Immuron Limited (IMRN), an Australian-based biopharmaceutical company, Wednesday, announced a new research collaboration with Monash ...

Immuron (IMRN) announced a new research collaboration agreement with Monash University. The major objective of this research collaboration is ...

Highlights: New Research Collaboration with Monash University One proposal will target Antimicrobial Resistant Pathways to develop broad spectrum therapeutic drug productsSecond project proposal will ...

Acurx Pharma receives positive regulatory guidance from EMA for ibezapolstat phase 3 programme for C. difficile infection: Staten Island, New York Tuesday, January 7, 2025, 18:00 ...

Acurx has now received positive written responses from the EMA (European Medicines Agency) under its Scientific Advice Procedure that the clinical, non-clinical and ...

Objective: To systematically evaluate the literature to determine whether vancomycin-induced neutropenia is dose- or duration-related and provide clinicians with feasible treatment alternatives.

Department of Burn, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China Objective: To analyze factors influencing the vancomycin trough concentration in burn patients to ...

“Our research shows off the coolness of the microbiome. Omadacycline caused a distinctly different effect on the microbiome than Vancomycin. This could explain why Omadacycline is a safe drug to give ...